Gapping up
Other news:
- ALT +20.8% (awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COV)
- INSU +19.5% (Insurance Acquisition Corp and Shift Technologies will combine)
- CNTG +19.3% (raises $250 mln in private placement by Temasek and other accredited investors)
- COTY +17.2% (confirms Kim Kardashian West strategic relationship to expand beauty brands globally BW)
- TLSA +12.6% (announces agreement with STC Biologics for GMP manufacturing of an anti-interleukin-6-receptor monoclonal antibody for clinical studies in patients with COVID-19)
- APTO +8.9% (FDA completed its review of the company's Investigational New Drug (IND) application and has granted IND allowance for the initiation of a Phase 1a/b clinical study of CG-806)
- KOS +8.6% (enters into crude oil prepayment agreement with Trafigura Trading worth up to $200 mln)
- NKLA +7.8% (confirms preorders will open June 29 at 11 a.m. ET; Nikola Badger EV pickup will debut at Nikola World 2020 in December)
- NEPT +7.4% (has been authorized by Health Canada to sell cannabis products to provinces and territories)
- MMP +4.5% (positive mention in Barron's )
- GRAF +4.5% (reportedly in talks to merge with Velodyne Lidar which makes sensors for self-driving vehicles and is backed by Ford (F) and Baidu (BIDU), according to Detroit News)
- FCEL +4.3% (notified POSCO Energy and Korea Fuel Cell that it has terminated License Agreements effective immediately)
- BP +3.4% (receives first regulatory approval for Duvroq (daprodustat) in Japan)
- BNTX +3.3% (raises $250 mln in private placement by Temasek and other accredited investors)
- RTX +3% (receives a $2.3 bln US Missile Defense Agency contract for seven GaN-based AN/TPY-2 radars)
- RCKT +3% (receives FDA clearance for its IND application for RP-L401)
- GILD +3% (provides update on remdesivir pricing)
- NEO +2.3% (launches comprehensive suite of solid tumor liquid biopsy tests for cancer patients)
- BSX +2.1% (receives FDA 510(K) clearance for the LUX-Dx insertable cardiac monitor system)
- INCY +1.5% (Japanese Ministry of Health, Labour and Welfare approved Tabrecta for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer)
- RGEN +1.3% (to acquire Albany, New York based Engineered Molding Technology)
- GSK +1.2% (receives first regulatory approval for Duvroq (daprodustat) in Japan)
- NVS +1.1% (receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare)
- CMCL +0.9% (raises quarterly dividend by 13% to $0.085 per share, up from prior dividend of $0.075 per share)
Analyst comments:
- LUV +3.5% (upgraded to Buy from Sell at Goldman)
- STM +2% (upgraded to Buy from Neutral at Bryan Garnier),
- GTLS +1.4% (upgraded to Outperform from In-line at Evercore ISI)